Chairman Shi Yuanyuan was invited to participate in the roundtable dialogue of the Cell and Gene Industry Development Forum
On December 14, Shi Yuanyuan, chairman of our company, was invited to participate in the roundtable dialogue of the 8th Shenzhen International Biomedical Industry Summit, Guangdong-Hong Kong-Macao Greater Bay Area Life Health Innovation Demonstration Area and Cell and Gene Industry Development Forum. The dialogue was chaired by Li Furong, Vice president of Shenzhen Biomedicine Promotion Association, and attended by Yu Li, Vice President of Shenzhen University General Hospital, Jiang Shu, chairman of Shenzhen Yinguan Biotechnology Co., LTD., Wang Mingjun, Executive Deputy General manager and CEO of Shenzhen Yinuo Immunology Co., LTD., Zhou Jun, Deputy general manager of Shenzhen Yinuo Biomedical Safety uation Institute Co., LTD.
The round table of the forum focuses on the theme of "The future of the cell and gene industry". "Challenges facing the development of cell and gene industry in Shenzhen", "non-clinical uation of cell and gene therapy products", "difficulties in the safety uation of cell drugs", "How to help cell therapy enterprises accelerate the industrialization process from the perspective of capital", "How to accelerate the pace of cell and gene drug industrialization in Shenzhen", "the collaborative development of cell and gene industry alliance" and other words The topic began, based on the actual industry, the guests analyzed the cell and gene industry policy, discussed the hot topics of biomedicine, and pointed out the current problems and opportunities in the cell and gene industry with their own industry experience and theoretical practice, and put forward many constructive suggestions. Chairman Shi Yuyuan introduced the differentiated development direction of Shenzhen Cell Valley as the only domestic reverse-virus carrier industrialization CRO/CDMO service platform in the field of cell and gene therapy, analyzed the development status and future development direction of Shenzhen's biomedical industry, and proposed that Shenzhen should make full use of the late advantages of cell gene therapy in the field of cell gene therapy and avoid departs. Low-key work, accumulate, strive for 3-5 years in the domestic and international cell and gene therapy field.
